Home

MICHAEL SETH ALTMAN

CIK 1746738 · Chief Financial Officer · last filed 2026-07-22

MICHAEL SETH ALTMAN is a Chief Financial Officer who has filed 16 SEC Form 4 insider transactions across 8 companies since 2020. The most recent filing, for FRNM, was dated Jul 22, 2026. Current disclosed insider exposure totals $3.4M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.42M

Companies

8

Total Filings

16

Lifetime Open-Market Net

$0

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
FRNM 2,352,500 — — $0 1 2026-07-22
ARYA Sciences Acquisition Corp IV (ARYD) Delisted Chief Financial Officer 0 $6.64 $0 $0 2 2024-07-31
NAUT Director 0 $0.98 $0 $0 4 2024-06-17
Lyra Therapeutics, Inc. (LYRA) Delisted Director — $0.70 — $0 5 2024-06-14
PCSC Chief Business Officer 286,250 $11.95 $3.42M $0 1 2024-06-13
ARYA Sciences Acquisition Corp V (ARYE) Delisted Chief Financial Officer 499,000 $10.36 $5.17M $0 1 2021-07-15
Nautilus Biotechnology, Inc. (ARYA) Delisted Chief Financial Officer 499,000 $11.16 $5.57M $0 1 2020-08-11
Cerevel Therapeutics Holdings, Inc. (CATB) Delisted Chief Financial Officer 499,000 $8.54 $4.26M $0 1 2020-06-09

Recent Filings

16 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-07-22 FRNM Conv (C) +2,066,250 $0 EDGAR
2024-07-31 ARYA Sciences Acquisition Corp IV (ARYD) Delisted Disp (D) −499,000 $0 EDGAR
2024-06-17 NAUT Grant (A) — $0 EDGAR
2024-06-14 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2024-06-13 PCSC Grant (A) +286,250 $2.86M EDGAR
2023-07-05 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2023-06-20 NAUT Grant (A) — $0 EDGAR
2022-06-21 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2022-06-17 NAUT Grant (A) — $0 EDGAR
2021-07-15 ARYA Sciences Acquisition Corp V (ARYE) Delisted Grant (A) +499,000 $4.99M EDGAR
Showing 1–10 of 16
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.